NEWS HIGHLIGHTSMedia Articles Related to Duoneb (Albuterol / Ipratropium)
COPD (Chronic Obstructive Pulmonary Disease) Quiz
Source: MedicineNet Alpha 1 Antitrypsin Deficiency Specialty [2017.09.20]
Title: COPD (Chronic Obstructive Pulmonary Disease) Quiz
Category: MedicineNet Quiz
Created: 10/8/2012 5:18:00 PM
Last Editorial Review: 9/20/2017 12:59:09 PM
Chronic Obstructive Pulmonary Disease (COPD)
Source: MedicineNet albuterol Specialty [2017.05.18]
Title: Chronic Obstructive Pulmonary Disease (COPD)
Category: Symptoms and Signs
Created: 4/28/2014 12:00:00 AM
Last Editorial Review: 5/18/2017 12:00:00 AM
COPD (Chronic Obstructive Pulmonary Disease)
Source: MedicineNet Allergic Cascade Specialty [2017.01.18]
Title: COPD (Chronic Obstructive Pulmonary Disease)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 1/18/2017 12:00:00 AM
Published Studies Related to Duoneb (Albuterol / Ipratropium)
Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. [2005.07]
Our study compared levalbuterol (LEV) to the combination of racemic albuterol (RAC) and ipratropium bromide (IB) in 140 patients aged 6-18 years presenting to a tertiary hospital Emergency Department with acute asthma and a peak expired flow rate (PEF)<80% predicted.In a sample of children with acute asthma and initial mean PEF<50% predicted, LEV was associated with less tachycardia but had no other advantage over RAC combined with IB.
The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. [2005.05]
BACKGROUND: The pathology of chronic obstructive pulmonary disease (COPD) includes both obstructive and inflammatory components. OBJECTIVE: The aim of this study was to confirm the findings of a previous study that compared the efficacy of a combination of 2 short-acting bronchodilators with the use of an inhaled corticosteroid and a long-acting beta-agonist in the treatment of COPD... CONCLUSION: In this 8-week study, subjects with moderate to severe COPD experienced greater improvements in lung function and symptom measures with FSC than with IB/ALB.
Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. [2004.10.23]
BACKGROUND: The issue of whether regular use of an inhaled beta2-adrenergic agonist worsens airflow and clinical outcomes in asthma is controversial. Retrospective studies have suggested that adverse effects occur in patients with a genetic polymorphism that results in homozygosity for arginine (Arg/Arg), rather than glycine (Gly/Gly), at aminoacid residue 16 of the beta2-adrenergic receptor. However, the existence of any genotype-dependent difference has not been tested in a prospective clinical trial... INTERPRETATION: Genotype at the 16th aminoacid residue of the beta2-adrenergic receptor affects the long-term response to albuterol use. Bronchodilator treatments avoiding albuterol may be appropriate for patients with the Arg/Arg genotype.
A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. [2004]
BACKGROUND: This is the first comparison of two combination therapies, fluticasone propionate/salmeterol and ipratropium bromide/albuterol (salbutamol), for the treatment of patients with COPD... CONCLUSIONS: Short-term treatment with the combined inhaled corticosteroid and long-acting beta(2)-adrenoceptor agonist fluticasone propionate/salmeterol resulted in greater control of lung function and symptoms than combined ipratropium bromide/albuterol bronchodilator therapy, in patients with COPD.
An evaluation of nebulized levalbuterol in stable COPD. [2003.09]
BACKGROUND: Levalbuterol, the R-isomer of albuterol, has advantages over racemic albuterol in asthma; however, the effectiveness of this beta-agonist in COPD has received little attention. OBJECTIVES: To evaluate the effectiveness of a single dose of nebulized levalbuterol in COPD. DESIGN: A randomized, double-blind, placebo-controlled trial comparing nebulized levalbuterol to racemic albuterol, combined racemic albuterol and ipratropium, and placebo. PATIENTS: Thirty patients with stable COPD (FEV(1) between 45% and 70% of predicted) were studied... CONCLUSION: For single-dose, as-needed use in COPD, there appears to be no advantage in using levalbuterol over conventional nebulized bronchodilators.
Clinical Trials Related to Duoneb (Albuterol / Ipratropium)
A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Completed]
Study to demonstrate the comparability of two puffs of Combivent hydrofluoroalkane (HFA)
inhalation aerosol (18 mcg ipratropium bromide/100 mcg albuterol sulfate / per puff) to two
puffs of the marketed chlorofluorocarbon (CFC) containing product, Combivent (CFC)
inhalation aerosol (18 mcg ipratropium bromide/103 mcg albuterol sulfate / per puff). The
dose response profile, safety and pharmacokinetics of Combivent HFA formulation are to be
characterized.
Combivent� HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease) [Terminated]
Study to evaluate the safety of combivent delivered in two different formulations
(hydrofluoroalkane (HFA) or chlorofluorocarbon (CFC)) from a metered dose inhaler (MDI),
using a cumulative dose response model in patients with COPD.
Comparison of Safety and Efficacy of COMBIVENT HFA to COMBIVENT (CFC) in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Terminated]
To compare the long-term (one-year) bronchodilator efficacy and safety of COMBIVENT
hydrofluoroalkane (HFA) Inhalation Aerosol to COMBIVENT chlorofluorocarbon (CFC) Inhalation
Aerosol and Placebo formulations of each in patients with COPD. In addition, steady state
pharmacokinetics over one dosing interval following four weeks of therapy will be
characterized.
Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects [Completed]
Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease [Completed]
The primary objective of this study was to compare the long-term (12-week) bronchodilator
efficacy and safety of ipratropium bromide / salbutamol combination administered by the
Respimat® 40 mcg / 200 mcg (one inhalation q. i.d.) to COMBIVENT Inhalation Aerosol (two
inhalations q. i.d.), ipratropium bromide Respimat® (one inhalation q. i.d.) and Placebo
formulations of each in patients with Chronic Obstructive Pulmonary Disease (COPD). An
additional objective was to show the superiority of Combivent Respimat as compared to
ipratropium bromide (40 mcg) Respimat. Steady state pharmacokinetics over one dosing
interval following four weeks of therapy were also characterized.
Reports of Suspected Duoneb (Albuterol / Ipratropium) Side Effects
Drug Ineffective (2),
Urticaria (2),
Chronic Obstructive Pulmonary Disease (2),
Tremor (2),
Contusion (1),
Wrong Drug Administered (1),
Oropharyngeal Pain (1),
Rash Pruritic (1),
Medication Error (1),
Dizziness (1), more >>
|
